Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Trane Technologies plc (TT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Trane Technologies plc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.19 (market cap $6.57B), while Trane Technologies plc trades at $471.85 (market cap $105.17B). The key difference: Trane Technologies plc is far larger — about 16× Iovance Biotherapeutics Inc. Common Stock's market cap, and Trane Technologies plc pays a 0.88% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| IOVA | TT | |
|---|---|---|
Market Cap | $6.57B | $105.17B |
Volume | 11,838,721 | 1,040,183 |
Sector | Health | Industrials |
52-Week High | $14.82 | $503.46 |
52-Week Low | $1.81 | $376.43 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $6.50B | $108.47B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Trane Technologies plc
Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.
Read more on TT →
